For research use only. Not for therapeutic Use.
Visugromab is aGDF-15 neutralizing IgG4 mAb. Visugromab exhibits potent effecicacy in PD-1/PD-L1 relapsed/refractory metastatic solid tumors[1].
| Catalog Number | I040859 |
| CAS Number | 2556646-63-8 |
| Purity | ≥95% |
| Reference | [1]. Necchi A, et al. Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER)[J]. 2023. |
